#India #Mumbai #Piramal Pharma #Q1 Performance #FY27 Results

Piramal Pharma Limited Reports Outstanding Q1 FY27 Results

Piramal Pharma Limited (NSE: PPLPHARMA), a notable player in the global pharmaceutical and health wellness sector, has unveiled its financial performance for the first quarter of FY27, ending on June 30, 2026. The company recorded a remarkable growth of 17% in revenue from operations, reaching ₹2,270 crores, compared to ₹1,934 crores in the same quarter of the previous year.

Key Financial Highlights

1. Revamped Revenue Streams: All three of Piramal's core business segments - Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Piramal Consumer Healthcare (PCH) - exhibited strong performance with the CDMO segment leading the growth with a 19% increase in revenue from ₹997 crores to ₹1,187 crores.

2. Excelling in EBITDA: The company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) surged significantly by 72% to ₹285 crores, with the EBITDA margin increasing to 12.5%, reflecting improved operating efficiencies and discipline in pricing strategies.

3. Post-Tax Performance: Despite facing challenges, the company reported a net loss after tax of ₹69 crores, a notable improvement from a loss of ₹102 crores during the same period last year. This improvement can be attributed to better operational performance and lower exceptional items encountered in the previous quarter.

Business Unit Highlights

• - Contract Development and Manufacturing Organization (CDMO): The CDMO division has seen broad-based growth, bolstered by healthy order inflows and enhanced execution capabilities across both domestic and international markets. The team has undertaken efforts to sharpen market coverage, expanding its commercial capabilities to drive further growth.

• - Complex Hospital Generics (CHG): Piramal continues to lead in the U.S. market for Inhalation Anesthesia, holding a 48% value share in the Sevoflurane segment. Additionally, the integration of Kenalog® is on track with expectations to begin supplies by Q2 FY27.

• - Piramal Consumer Healthcare (PCH): The consumer healthcare segment has reported robust growth, with Power Brands experiencing a remarkable 23% year-over-year increase, contributing to 53% of healthcare sales. The e-commerce channel also saw substantial growth of 40%, making up 28% of total sales.

Forward Outlook

Nandini Piramal, Chairperson of the company, expressed optimism about the upcoming fiscal year, highlighting the effective execution strategies that have paved the way for revenue growth and margins expansion. She acknowledged the dynamic external environment but reassured stakeholders of the company’s ability to adapt and thrive amid challenges.

In concluding remarks, she stated, "We look forward to delivering sustained revenue growth and EBITDA expansion throughout FY27, driven by a focused approach and commitment to operational excellence."

Conclusion

Piramal Pharma's impressive Q1 performance is indicative of its strong operational strategies and good market positioning across its sectors. The firm remains dedicated to enhancing its operational efficacy while continuing to meet the needs of its diverse portfolio of products and services, ensuring it caters effectively to market demands.

This quarter showcases Piramal Pharma as a resilient player in the pharmaceutical industry, capable of navigating through uncertainty while achieving significant results.